Home › Companies › ATEA PHARMACEUTICALS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ATEA PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 20, 2025: 5 items on ATEA PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2025: 5 passed (calculated).
Significant dissent: 3 directors (30.4%, 21.3%, 21.2% against).
Notable dissent: 1 say-on-pay vote (79.3% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: BML Capital (13F, 8.4%, as of September 30, 2026)
Explore ATEA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are ATEA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bruno Lucidi | 46,640,587 | -- | -- | 12,559,084 | 15,781,736 | 79% | Passed (calculated) | — |
| Elect Director: Polly Murphy, DVM, PhD | 41,184,263 | -- | -- | 18,015,408 | 15,781,736 | 70% | Passed (calculated) | — |
| Elect Director: Bruce Polsky, MD, MACP, FIDSA | 46,597,653 | -- | -- | 12,602,018 | 15,781,736 | 79% | Passed (calculated) | — |
| 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 | 73,766,274 | 1,192,659 | 22,474 | -- | 0 | 98% | Passed (calculated) | — |
| 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers | 46,450,302 | 12,107,029 | 642,340 | -- | 15,781,736 | 79% | Passed (calculated) | — |
Source: ATEA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 20, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
119 asset managers disclosed a vote on at least one ATEA PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Bruce Polsky, MD, MACP, FIDSA
ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bruce Polsky, MD, MACP, FIDSA”): 46,597,653 for, 12,602,018 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 15,155,741 for, 137,333 withheld, 11,984 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,765,568 | 0 | 0 | 0 | For |
| Fidelity | 3,982,987 | 0 | 0 | 0 | For |
| BlackRock | 3,647,018 | 0 | 0 | 0 | For |
| Charles Schwab | 621,155 | 0 | 0 | 0 | For |
| JPMorgan | 288,714 | 0 | 0 | 0 | For |
| Equitable | 138,793 | 0 | 0 | 119,220 | Mixed |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| American Century | 163,093 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 133,300 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
| Goldman Sachs | 131,537 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 96,017 | 0 | 0 | 0 | For |
| Lincoln Financial | 78,650 | 0 | 0 | 4,025 | For |
| MASTER INVESTMENT PORTFOLIO | 70,325 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 70,000 | 0 | 0 | 0 | For |
| Brighthouse | 65,514 | 0 | 0 | 0 | For |
| Nationwide | 64,479 | 0 | 0 | 0 | For |
| T. Rowe Price | 50,656 | 0 | 0 | 0 | For |
| Global X | 46,292 | 0 | 0 | 0 | For |
| Voya | 44,486 | 0 | 0 | 0 | For |
| Northern Trust | 40,817 | 0 | 0 | 0 | For |
| Pacific Life | 39,227 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,183 | 0 | 0 | 0 | For |
| Invesco | 34,510 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 33,201 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Bruno Lucidi
ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bruno Lucidi”): 46,640,587 for, 12,559,084 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 15,155,741 for, 137,333 withheld, 11,984 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,765,568 | 0 | 0 | 0 | For |
| Fidelity | 3,982,987 | 0 | 0 | 0 | For |
| BlackRock | 3,647,018 | 0 | 0 | 0 | For |
| Charles Schwab | 621,155 | 0 | 0 | 0 | For |
| JPMorgan | 288,714 | 0 | 0 | 0 | For |
| Equitable | 138,793 | 0 | 0 | 119,220 | Mixed |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| American Century | 163,093 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 133,300 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
| Goldman Sachs | 131,537 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 96,017 | 0 | 0 | 0 | For |
| Lincoln Financial | 78,650 | 0 | 0 | 4,025 | For |
| MASTER INVESTMENT PORTFOLIO | 70,325 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 70,000 | 0 | 0 | 0 | For |
| Brighthouse | 65,514 | 0 | 0 | 0 | For |
| Nationwide | 64,479 | 0 | 0 | 0 | For |
| T. Rowe Price | 50,656 | 0 | 0 | 0 | For |
| Global X | 46,292 | 0 | 0 | 0 | For |
| Voya | 44,486 | 0 | 0 | 0 | For |
| Northern Trust | 40,817 | 0 | 0 | 0 | For |
| Pacific Life | 39,227 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,183 | 0 | 0 | 0 | For |
| Invesco | 34,510 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 33,201 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
70% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Polly Murphy, DVM, PhD
ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Polly Murphy, DVM, PhD”): 41,184,263 for, 18,015,408 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 14,180,450 for, 1,075,524 withheld, 49,084 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,765,568 | 0 | 0 | 0 | For |
| Fidelity | 3,979,498 | 0 | 0 | 3,489 | For |
| BlackRock | 3,647,018 | 0 | 0 | 0 | For |
| Charles Schwab | 621,155 | 0 | 0 | 0 | For |
| JPMorgan | 288,714 | 0 | 0 | 0 | For |
| Equitable | 138,793 | 0 | 0 | 119,220 | Mixed |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 163,093 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 133,300 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 131,537 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 96,017 | Withhold |
| Lincoln Financial | 78,650 | 0 | 0 | 4,025 | For |
| MASTER INVESTMENT PORTFOLIO | 70,325 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 70,000 | Withhold |
| Brighthouse | 42,429 | 0 | 0 | 23,085 | Mixed |
| Nationwide | 21,608 | 0 | 0 | 42,871 | Mixed |
| T. Rowe Price | 50,656 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 46,292 | Withhold |
| Voya | 0 | 0 | 0 | 44,486 | Withhold |
| Northern Trust | 0 | 0 | 0 | 40,817 | Withhold |
| Pacific Life | 39,227 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,183 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 34,510 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 33,201 | Withhold |
Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY.
ATEA PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 46,450,302 for, 12,107,029 against, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,765,568 | 0 | 0 | 0 | For |
| Fidelity | 3,982,987 | 0 | 0 | 0 | For |
| BlackRock | 3,647,018 | 0 | 0 | 0 | For |
| Charles Schwab | 621,155 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 288,714 | 0 | 0 | Against |
| Equitable | 258,013 | 0 | 0 | 0 | For |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| American Century | 0 | 163,093 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 133,300 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
| Goldman Sachs | 131,537 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 96,017 | 0 | 0 | 0 | For |
| Lincoln Financial | 61,625 | 21,050 | 0 | 0 | Mixed |
| MASTER INVESTMENT PORTFOLIO | 70,325 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 70,000 | 0 | 0 | 0 | For |
| Brighthouse | 23,085 | 42,429 | 0 | 0 | Mixed |
| Nationwide | 64,479 | 0 | 0 | 0 | For |
| T. Rowe Price | 50,656 | 0 | 0 | 0 | For |
| Global X | 46,292 | 0 | 0 | 0 | For |
| Voya | 44,486 | 0 | 0 | 0 | For |
| Northern Trust | 40,817 | 0 | 0 | 0 | For |
| Pacific Life | 39,227 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,183 | 0 | 0 | 0 | For |
| Invesco | 34,510 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 33,201 | 0 | 0 | 0 | For |
Fund voting reports, all 43 managers: 14,652,211 for, 656,100 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,015,477 | 0 | 0 | 0 | For |
| BlackRock | 3,315,373 | 671 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,932,350 | 0 | 0 | 0 | For |
| State Street | 1,406,710 | 3,213 | 0 | 0 | For |
| Renaissance | 1,053,679 | 0 | 0 | 0 | For |
| Charles Schwab | 621,303 | 0 | 0 | 0 | For |
| Newtyn Management, LLC | 580,000 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 565,076 | 0 | 0 | Against |
| Northern Trust | 432,950 | 0 | 0 | 0 | For |
| Two Sigma | 423,858 | 0 | 0 | 0 | For |
| Nuveen | 255,847 | 0 | 0 | 0 | For |
| DE Shaw | 255,554 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 237,800 | 0 | 0 | 0 | For |
| Wellington | 221,694 | 0 | 0 | 0 | For |
| American Century | 0 | 163,093 | 0 | 0 | Against |
| Dimensional | 156,281 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 147,137 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 143,100 | 0 | 0 | Against |
| AllianceBernstein | 119,220 | 0 | 0 | 0 | For |
| Point72 | 116,734 | 0 | 0 | 0 | For |
| STRS OHIO | 105,500 | 0 | 0 | 0 | For |
| Maryland State Retirement & Pension System | 94,445 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 93,800 | 0 | 0 | 0 | For |
| Vanguard | 89,081 | 0 | 0 | 0 | For |
Institutional-manager reports, all 91 managers: 20,920,139 for, 1,033,891 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
ATEA PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 73,766,274 for, 1,192,659 against, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 43 asset managers below reported 15,308,311 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,765,568 | 0 | 0 | 0 | For |
| Fidelity | 3,982,987 | 0 | 0 | 0 | For |
| BlackRock | 3,647,018 | 0 | 0 | 0 | For |
| Charles Schwab | 621,155 | 0 | 0 | 0 | For |
| JPMorgan | 288,714 | 0 | 0 | 0 | For |
| Equitable | 258,013 | 0 | 0 | 0 | For |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| American Century | 163,093 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 133,300 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
| Goldman Sachs | 131,537 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 96,017 | 0 | 0 | 0 | For |
| Lincoln Financial | 82,675 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 70,325 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 70,000 | 0 | 0 | 0 | For |
| Brighthouse | 65,514 | 0 | 0 | 0 | For |
| Nationwide | 64,479 | 0 | 0 | 0 | For |
| T. Rowe Price | 50,656 | 0 | 0 | 0 | For |
| Global X | 46,292 | 0 | 0 | 0 | For |
| Voya | 44,486 | 0 | 0 | 0 | For |
| Northern Trust | 40,817 | 0 | 0 | 0 | For |
| Pacific Life | 39,227 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,183 | 0 | 0 | 0 | For |
| Invesco | 34,510 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 33,201 | 0 | 0 | 0 | For |
Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 85,579,475 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.57% |
| 2 | Fidelity | 4.65% |
| 3 | BlackRock | 4.26% |
| 4 | Charles Schwab | 0.73% |
| 5 | JPMorgan | 0.34% |
| 6 | Equitable | 0.30% |
| 7 | TIAA | 0.30% |
| 8 | American Century | 0.19% |
| 9 | BRIDGEWAY FUNDS INC | 0.16% |
| 10 | QUANTITATIVE MASTER SERIES LLC | 0.15% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 7.03% |
| 2 | BlackRock | 3.87% |
| 3 | Bain Capital Life Sciences Investors, LLC | 2.90% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2.26% |
| 5 | State Street | 1.65% |
| 6 | Renaissance | 1.23% |
| 7 | Charles Schwab | 0.73% |
| 8 | Newtyn Management, LLC | 0.68% |
| 9 | JPMorgan | 0.66% |
| 10 | Northern Trust | 0.51% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 8,943,065 | 10.45% | Form 13F, quarter ended March 31, 2025 |
| Jean-Pierre Sommadossi | 8,876,453 | 10.37% | Schedule 13G, filed May 14, 2025 |
| BML Investment Partners, L.P. | 7,490,000 | 8.75% | Schedule 13G, filed February 9, 2026 |
| FMR LLC | 6,618,297 | 7.73% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| FMR (Fidelity) | 6,018,019 | 7.03% | Form 13F, quarter ended March 31, 2025 |
| JPM Partners LLC | 5,866,025 | 6.85% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| Vanguard Group | 4,727,702 | 5.52% | Form 13F, quarter ended March 31, 2025 |
| Radoff Bradley Louis | 3,380,100 | 3.95% | Schedule 13D, filed April 17, 2025 |
| Geode Capital | 1,977,337 | 2.31% | Form 13F, quarter ended March 31, 2025 |
| State Street | 1,770,688 | 2.07% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 85,579,475 shares outstanding, as reported by ATEA PHARMACEUTICALS INC. on its Form 10-Q dated May 9, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ATEA PHARMACEUTICALS INC.'s shareholder meeting held June 20, 2025, in the 2024-2025 proxy season, 119 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 777 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE… — FOR was 79% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ATEA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ATEA PHARMACEUTICALS INC.’s 10-Q dated May 9, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ATEA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “ATEA PHARMACEUTICALS (AVIR) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/atea-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.